Share
 
Title
Code
Session Type
Venue
Date Time
Co-Chairs:
16:30
THAB0201
Who benefited most from immediate treatment in START? A subgroup analysis
Jean-Michel Molina, University of Paris Diderot, France
Abstract
Slides

16:45
THAB0202
Increased risk of suicidal behaviour with use of efavirenz: results from the START trial
Alejandro Arenas-Pinto, University College London, United Kingdom
Abstract
Slides

17:00
THAB0203
STRIIVING: switching to abacavir/dolutegravir/lamivudine fixed dose combination (ABC/DTG/3TC FDC) from a PI, INI or NNRTI based regimen maintains HIV suppression at week 48
Michael Aboud, ViiV Healthcare, United Kingdom
Abstract
Slides

17:15
THAB0204
Experiences with long-acting injectable ART: a qualitative study among people living with HIV participating in a phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
Deanna Kerrigan, Johns Hopkins University, United States
Abstract
Slides

17:30
THAB0205LB
Superior efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) compared with ritonavir (RTV) boosted atazanavir (ATV) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naïve women with HIV-1 infection (ARIA Study)
Catherine Orrell, University of Cape Town, South Africa
Abstract
17:45
THAB0206LB
Cabotegravir + rilpivirine as long-acting maintenance therapy: LATTE‑2 week 48 results
David Margolis, ViiV Healthcare, United States
Abstract
Slides